178 results about "Adipogenesis" patented technology

This invention also provides a purified or isolated population of ADSCs that can differentiate into a cell of the leiomyogenic lineage, e.g., smooth muscle or skeletal muscle. In yet another aspect, the population additionally can be differentiated into a lineage selected from the group consisting of osteogenic, adipogenic, chondrogenic, myogenic and neuronal. This invention further provides a composition comprising a substantially homogeneous expanded population of smooth muscle cells. This invention provides a composition comprising a substantially homogeneous expanded population of skeletal muscle cells. Also provided herein is an isolated composition comprising a purified adipose-derived stem cell (ADSC) or progeny of said ADSC and an effective amount of laminin or heparin, effective to induce leiomyogenic differentiation. Diagnositic and therapeutic uses for these compositions are provided herein.

A method for preventing obesity related to infection by an adipogenic adenovirus includes assaying a sample from a person to determine whether the person has been previously infected with an adipogenic adenovirus, and if the person has not been previously infected, providing the person with at least one sensor positioned to detect when a person's hand approaches a predetermined distance from the person's face. By warning the person of undesired hand-to-face contacts, the person is able to reduce the incidence of obesity related infections. Other embodiments are directed to a kit for preventing obesity caused by infection with an adipogenic adenovirus, such kit including a container for assaying an agent indicating the presence of antibodies to Ad-36, and a sensor positioned on an item selected from the group consisting of one of a hat, a writing instrument, eye glasses, a belt, sunglasses, a bra, a shirt, and a tie.

The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and / or long term regulation of energy balance; short-, medium- and / or long term regulation (stimulation and / or inhibition) of food intake; adipogenesis, adiposity and / or obesity; body weight gain and / or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and / or gastrectomy (ghrelin replacement therapy).

This invention also provides a purified or isolated population of ADSCs that can differentiate into a cell of the leiomyogenic lineage, e.g., smooth muscle or skeletal muscle. In yet another aspect, the population additionally can be differentiated into a lineage selected from the group consisting of osteogenic, adipogenic, chondrogenic, myogenic and neuronal. This invention further provides a composition comprising a substantially homogeneous expanded population of smooth muscle cells. This invention provides a composition comprising a substantially homogeneous expanded population of skeletal muscle cells. Also provided herein is an isolated composition comprising a purified adipose-derived stem cell (ADSC) or progeny of said ADSC and an effective amount of laminin or heparin, effective to induce leiomyogenic differentiation. Diagnositic and therapeutic uses for these compositions are provided herein.

Methods and compositions for treating obesity and related disorders. The methods include the use of Sca-1+ progenitor cells treated with BMP-2, -4, -5, -6, and / or -7.

A method for preventing obesity related to infection by an adipogenic adenovirus includes obtaining a sample from a person, assaying the sample to determine whether the person has been previously infected with an adipogenic adenovirus, and if the person has not been previously infected, providing the person with at least one sensor positioned to detect when a person's hand approaches a predetermined distance from the person's face. By warning the person of undesired hand-to-face contacts, the person is able to reduce the incidence of obesity related infections. Other embodiments are directed to a kit for preventing obesity caused by infection with an adipogenic, adenovirus, such kit including a container for assaying an agent indicating the presence of antibodies to Ad-36, and a sensor positioned on an item selected from the group consisting of one of a hat, a writing instrument, eye glasses, a belt, sunglasses, a bra, a shirt, and a tie.

The present invention discloses osteogenic and anti-adipogenic oxysterols. Agents and methods for protecting, blocking or rescuing marrow stromal cells from the inhibitory effects of oxidative stress on their osteoblastic cellular differentiation are disclosed. Exemplary agents include oxysterols alone or in synergistic combinations, as well as hedgehog or Wnt signaling activators. The synergistic effects of oxysterols and bone morphogenic proteins are also disclosed.

The invention provides (i) a method of treating metabolic syndrome in an animal, (ii) a method of suppressing the appetite of an animal, (iii) a method of treating obesity in an animal, (iv) a method of reducing the weight of an animal in need thereof, (v) a method of reducing a blood lipid level in an animal in need thereof, (vi) a method of treating non-alcoholic steatohepatitis in an animal, and (vii) a method of inhibiting adipogenesis. The methods comprise administering an effective amount of an active ingredient, wherein the active ingredient comprises a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal. The invention also provides a kit comprising a container holding a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them; and instructions for administration. The diketopiperazines have the formula given in the application.

This invention relates, e.g., to a synthetic compound, Oxy149, having the structure (Formula I) or a bioactive or pharmaceutical composition comprising Oxy149 and a pharmaceutically acceptable carrier. Methods are also disclosed for using the compound or bioactive or pharmaceutical composition to treat a variety of disorders, including e.g. bone disorders, obesity, cardiovascular disorders, and neurological disorders. Oxy149 can be delivered either locally or systemically.

The present invention relates to methods for prevention and / or treatment of metabolic disorders, post-menopausal obesity and conditions associated with high fat diet consumption including, obesity, body weight gain, fat mass formation, bone mineral content reduction, white adipose tissue weight gain, increased cholesterol levels, increased leptin levels, insulin resistance, type II diabetes, increased blood glucose levels, inflammatory diseases, cardiovascular diseases, fatty liver condition (accumulation of fat in the liver), decreased uncoupling protein-1 (UCP-1) levels and increased lipogenesis.

The present invention provides compounds, compositions, and methods for identification of motifs within regulatory regions of genes involved in adipogenesis and adipocyte differentiation. Compounds and compositions are provided for modulating expression of nuclear receptor / transcription factor-regulated genes. Methods for modulating the function of PPAR-γ as well as PPAR-γ-regulated gene promoters, and methods of using oligomeric compounds for diagnosis and treatment of diseases such as obesity and diabetes are also provided.

A wearable apparatus for the treatment or prevention of osteopenia or osteoporosis, stimulating bone growth, preserving or improving bone mineral density, and inhibiting adipogenesis is disclosed where the apparatus may generally comprise one or more vibrating elements configured for imparting repeated mechanical loads to the hip, femur, and / or spine of an individual at a frequency and acceleration sufficient for therapeutic effect. These vibrating elements may be secured to the upper body of an individual via one or more respective securing mechanisms, where the securing mechanisms are configured to position the one or more vibrating elements in a direction lateral to the individual, and the position, tension, and efficacy of these vibrating elements may be monitored and / or regulated by one or more accelerometers.

Provided herein are stem cells and methods for producing a culture of stem cells from urine. The stem cells may be differentiated into an osteogenic, chondrogenic, adipogenic, endothelial, neurogenic or myogenic lineage. Methods of use of the cells are provided, including methods of treating a subject in need of a cell based therapy.

The invention provides (i) a method of treating metabolic syndrome in an animal, (ii) a method of suppressing the appetite of an animal, (iii) a method of treating obesity in an animal, (iv) a method of reducing the weight of an animal in need thereof, (v) a method of reducing a blood lipid level in an animal in need thereof, (vi) a method of treating non-alcoholic steatohepatitis in an animal, and (vii) a method of inhibiting adipogenesis. The methods comprise administering an effective amount of an active ingredient, wherein the active ingredient comprises a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal. The invention also provides a kit comprising a container holding a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them; and instructions for administration. The diketopiperazines have the formula given in the application.

Cellfree adipose tissue extracts, implants including the same and methods for the preparation thereof. The extracts and implants are capable of inducing adipogenesis and angiogenesis and are, thus, useful in applications including soft tissue repair and engineering and angiogenesis induction, e.g., in wound healing, treatment of burn injuries and ischemic conditions.

The invention discloses a human mesenchymal stem cell adipogenesis inducing and differentiating culture medium and a preparation method thereof. The human mesenchymal stem cell adipogenesis inducing and differentiating culture medium is produced by the following components of an alpha-MEM / HG-DMEM culture medium, 5-50% of percent by volume of fetal calf serum, 0.5-10% of percent by volume of glutamine, 100-400 [mu]M volume of indomethacin, insulin with the concentration of 0.1-20 [mu]g / ml, 10-200 [mu]M volume of 1-methyl-3-isobutyl xanthine, 10-200 nM volume of dexamethasone and 0.1-20 [mu]M volume of spermine. The preparation method includes the following steps that a culture dish is cleaned; the culture medium is provided, and the alpha-MEM / HG-DMEM culture medium is prepared in the culture dish according to a formula; materials are mixed; and mixed liquor is filtered. Multiple histologic origin human mesenchymal stem cells including human mesenchymal stem cells, umbilical cord mesenchymal stem cells and adipose tissue-derived stromal cells are induced to the directional differentiation of adipogenesis cells; differentiating and inducing time of the human mesenchymal stem cells isshortened, the preparation method is convenient, and the differentiating and the inducing of human mesenchymal stem cell adipogenesis can be achieved stably and efficiently.

The invention provides a nutrient composition capable of controlling high blood sugar of crowds suffering from type 2 diabetes and improving immunity. The nutrient composition is prepared from the following raw materials in parts by weight: 1-20 parts of a navy bean extract, 10-15 parts of inulin, 5-10 parts of resistant dextrin, 0.5-1 part of xylooligosaccharide, 0.2-0.5 part of ginseng, 0.2-0.5part of resveratrol, 2-60 parts of rhizoma polygonati, 0.5-1 part of kudzuvine roots, 0.05-0.8 part of bovine coloctrum, 0.2-0.4 part of beer yeast, 1-1.2 parts of wheat oligopeptide, 0.06-0.09 part of bitter gourd polypeptide, 0.01-0.03 part of lutein esters, 0.01-0.02 part of taurine, 0.01-0.014 part of vitamin B1, 0.01-0.014 part of vitamin B2, 0.01-0.014 part of vitamin B6, 0.00012-0.00024 part of vitamin B12 and 4-8 parts of Isomalt. The nutrient composition provided by the invention is scientifically prepared for the crowds suffering from type 2 diabetes, can solve the problem of maintaining nutrients comprehensive and balanced, can quickly and effectively control a forming mechanism for converting starch foods into sugar and a forming mechanism for converting starch foods into fat,and has the efficacy of quickly regulating blood sugar, controlling body weight, improving immunity of organisms, resisting weariness, regulating blood fat, improving osteoporosis, invigorating the kidney, tonifying the kidney and the like.

Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis. Ad-36 E4 orf 1 protein can be used to increase insulin sensitivity and ameliorate diabetes. Additionally, drugs that mimic the action of Ad-36 E4 orf 1 protein could be found. Ad-36 E4 orf 1 could also be used to increase fat cells in lipodystrophy. We have also discovered that Ad-36 infection in human skeletal muscle cells increased differentiation and insulin independent glucose uptake. It is expected that infection with Ad-36 E4 orf 1 gene will also cause these effects.

The invention provides a serum-free culture medium for umbilical cord mesenchymal stem cells. The serum-free culture medium is characterized by comprising a DMEM low-sugar culture medium, transferrin, serum albumin, insulin, platelet-derived growth factors, epidermal growth factors, transforming growth factors, beta-mercaptoethanol, dihydromyricetin and catechin. The invention belongs to the technical field of stem cell culture. The serum-free culture medium for umbilical cord mesenchymal stem cells, provided by the invention, can obviously promote the adherence performance and multiplication rate of the umbilical cord mesenchymal stem cells, is beneficial to the multiplication of the umbilical cord mesenchymal stem cells and the maintenance of features of the stem cells, is excellent in adipogenesis and osteogenic induction differentiation potential, is relatively simple in component of the culture medium and is relatively low in cost.

The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and / or long term regulation of energy balance; short-, medium- and / or long term regulation (stimulation and / or inhibition) of food intake; adipogenesis, adiposity and / or obesity; body weight gain and / or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and / or gastrectomy (ghrelin replacement therapy).

The invention discloses an identification and preparation method and application CD106-positive mesenchymal stem cells. The method comprises the following steps: identifying and isolating CD106-positive cells from mononuclear cells isolated from bone marrow, placenta or other tissues through an immunological method, carrying out adherent culture, and collecting adherent CD106-positive cells; or carrying out adherent culture of mononuclear cells isolated from bone marrow, placenta or other tissues, collecting adherent mesenchymal cells, and isolating the CD106-positive mesenchymal stem cells when the count of the obtained cells is large enough. The CD106-positive cells are mesenchymal stem cells with adherent growth, express mesenchymal stem cell-related immunological phenotype, and have osteogenesis, adipogenesis and other differentiation potencies. Compared with CD106-negative mesenchymal stem cells, the CD106-positive cells have higher immunosuppression capacity, can better inhibit proliferation of IFN-gamma (interferon-gamma) secretion of lymphocytes, and can be used for treating graft versus host disease (GVHD) and autoimmune diseases.

The invention provides a method for separating umbilical cord mesenchymal stem cell simply and effectively, which comprises the steps of separating umbilical cord mesenchymal stem cell with cannulas, digesting umbilical cord mesenchymal stem cell with trypLETM and cultivating umbilical cord mesenchymal stem cell with a serum-free medium. According to the method, an umbilical cord mesenchymal stem cell from a mother's body completely can be obtained relatively fast, and damage on the cell is relatively low; tests show that according to the method, mesenchymal stem cell can be protected to the most extent, the motility rate as well as the activity is relatively high, and adipogenesis and osteogenic induced differentiation can be carried out effectively.

The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and / or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular alcohol disorder, drug abuse, growth retardation, cachexia, short-, medium-, and / or long term regulation of energy balance, short-, medium-, and / or long term regulation (stimulation and / or inhibition) of food intake, intake of rewarding food, adipogenesis, adiposity and / or obesity, body weight gain and / or reduction, diabetes, diabetes type I, diabetes type II, tumor cell proliferation, inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and / or gastrectomy (ghrelin replacement therapy).

Provided is a device comprising at least two layers, said at least two layers being at least partially overlapping (e.g., superposed) and contacting one another, wherein a first layer of said at least two layers comprises a non-biodegradable mesh, and wherein a second layer of the at least two layers comprises an electrospun element, and wherein the device is devoid of an extracellular matrix generated by mesenchymal progenitor cells, which are characterized by a reduced differentiation potential into an adipogenic lineage by at least about 50% as compared to differentiation potential of mesenchymal stem cells from an adult adipose source under identical assay conditions, and by an increased osteogenic differentiation potential by at least about 20% as compared to the osteogenic differentiation potential of adipose-derived MSCs under identical assays conditions.

The invention discloses a mesenchymal stem cell adipogenesis induced differentiation method. The method includes the following steps: (1) recovering the mesenchymal stem cells to grow to 70-90%; (2) digesting the mesenchymal stem cells and culturing for 1-3 days by using a complete culture medium; and (3) when the cell fusion degree reaches 70-90%, sucking off the complete culture medium, adding amesenchymal stem cell fat-forming induction differentiation culture medium (composed of DMEM / F12 basal culture medium, fetal bovine serum with volume concentration of 8-12%, 8-12 ug / ml of insulin, 1%. of penicillin, 1 %. of streptomycin, 0.8-1.2 umol / L of dexamethasone, 100-500 umol / L of 3-isobutyl-1-methylxanthine) for culture, and changing the culture medium every 3-4 days; preforming continuous induction, which depends on cell growth and adipogenesis condition. The method is proper in operation, simplifies the steps of induced differentiation and is quite high in adipogenesis induced differentiation rate.

The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-α), Interleukin-6 (IL-6) and Interleukin-1 (IL-1β).

The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

An apparatus for the treatment or prevention of osteopenia and osteoporosis, stimulating bone growth, preserving or improving bone mineral density, and inhibiting adipogenesis is described where one embodiment may comprise a motor configured to be in vibrational conductance with an area of the subject, one or more sensors in communication with the motor for receiving feedback relating to the vibrational conductance, and a controller in communication with the motor. The controller may be configured to receive the feedback through the one or more sensors and determine an amount of vibrational conductance transmitted to the area of the subject such that the feedback is correlated to a fit of the motor relative to the area of the subject. Additionally, the controller may be further configured to adjust one or more parameters of the motor in response to the correlated fit until the feedback is optimized within a predetermined range for treatment.

The invention discloses an induction medium inducing transdifferentiation of fibroblast into adipocyte, an induction method and application thereof. The induction medium contains a basal culture medium and an induction micromolecule combination, wherein the induction micromolecule combination is SG or 6TF, S is SB431542, G is GSK126, 6 is E61541, T is tranylcypromine, and F is forskolin. The induction medium can induce and trans-differentiate the fibrolast into the adipocyte, the obtained adipocyte contains a normal adipocyte specificity molecular tag and has a normal fat adipogenesis function, and a new approach is provided for solving the cellular source problem of regenerative medicine.